Biotech vet Gilman’s startup earns $190M-plus in Roche deal

"Honest to God, there are dozens of targets we could hit. We can afford to be generous and give a partner like Roche whatever they want," Arrakis CEO Michael Gilman said of the Roche collaboration, in which the privately held startup will help Roche develop drugs that target RNA, the element inside molecules that uses DNA instructions to create proteins. Roche will have exclusive rights to test and commercialize any drug candidates.